Skip to search formSkip to main contentSkip to account menu

Antineoplastic Agent Combination SM-88

Known as: SM-88 
An orally bioavailable, proprietary combination of four agents with potential antineoplastic activity. Although the four agents and their exact… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage.
200 Background: SM-88 (tyrosine derivative [Td], mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively… 
2019
2019
Phase II monotherapy efficacy of cancer metabolism targeting SM-88 in heavily pre-treated PDAC patients
Abstract Background SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN]) is a relatively non-toxic, targeted therapy based on the… 
2019
2019
Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer
Background: A wide range of cancers, including pancreatic cancer, display altered expression of amino acid transporter LAT-1. LAT… 
2019
2019
SM-88 therapy in high-risk poor prognosis pancreatic cancer (PDAC).
e15714 Background: Refractory PDAC has no established therapy (JCO 37, 2019 supp 4; 226). SM-88 (D,L-alpha-metyrosine) is a novel… 
2019
2019
Novel Therapy Elicits Responses in Pancreatic Cancer.
The novel drug SM-88 seems to be a promising therapy for previously treated patients with advanced pancreatic ductal… 
2019
2019
Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.
83 Background: Absolute PSA change is an imperfect surrogate of clinical benefit; CTCs and PSA doubling time (DT) may also be… 
2019
2019
Typical hormone deprivation side effects compared to SM-88 therapy for rising PSA.
79 Background: Treatment for rising PSA non-metastatic prostate cancer (nmPC) includes multifaceted hormone therapies (HT… 
2018
2018
SM-88 therapy in patients with advanced or metastatic pancreatic cancer.
457Background: SM-88 (tyrosine derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non… 
Review
2018
Review
2018
SM-88 efficacy and safety in metastatic breast cancers.
e13100Background: SM-88 is a relatively non-toxic novel combination therapy (dysfunctional tyrosine, CYP3a4 inducer, mTOR… 
2018
2018
SM-88 in advanced cancers of the pancreas (SMACP).
TPS4156Background: Treatment options for recurrent/refractory advanced pancreatic cancer (PC) include largely ineffective toxic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)